Clinical Trial Update: A Study to Measure the Effect of Tolterodine Extended Release on the Thickness of the Bladder Wall in Patients With Overactive Bladder [Phase 4]

View source ↗

Summary

Phase 4 trial assessing the effect of tolterodine extended release on bladder wall thickness in patients with urinary incontinence.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder
• Urinary Incontinence

Drugs mentioned

• Tolterodine Extended Release (tolterodine extended release)

Snippet

Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Conditions: Urinary Incontinence | Phase 4 | Status: COMPLETED